Goldline Pharmaceutical IPO Subscription Status Day-3: Live Bidding

Goldline Pharmaceutical IPO subscription began on Tuesday, May 12, 2026, and the public issue will remain open for bidding until May 14, 2026. The company plans to raise approximately ₹11.61 crores through this SME IPO. Goldline Pharmaceutical has allocated 35% of the issue for retail investors, while Qualified Institutional Buyers (QIBs) hold a 50% reservation and Non-Institutional Investors (NIIs) are allotted 15% of the total issue size.

The IPO price band has been fixed between ₹41 and ₹43 per equity share. Investors looking to apply in the retail category will need to bid for a minimum lot of 6,000 shares. Based on the upper price band, the minimum investment amount required comes to ₹2,58,000.

Goldline Pharmaceutical IPO Subscription Status – Day 3

Goldline Pharmaceutical Ltd. is a fast-growing pharmaceutical company operating across 9 states in India, including Maharashtra, Chhattisgarh, Madhya Pradesh, Odisha, Tamil Nadu, Rajasthan, Jharkhand, Goa, and Bihar. Established with a strong vision of delivering quality healthcare solutions, the company has built a solid presence in the Indian pharma market through consistent expansion and a well-structured distribution network. Its operations are driven by strong marketing principles, supported by an experienced product management team and a dedicated field force that ensures steady market growth and wider product reach.

Founded in 2005 in Nagpur by visionary entrepreneur Mr. Amol Mujumdar, Goldline Pharmaceutical has developed a strong portfolio of therapeutic brands and innovative formulations. The company focuses on continuous product development, brand extensions, and new drug delivery systems to meet evolving healthcare needs. With a people-centric approach, it emphasizes employee motivation, skill development, and organizational growth, ensuring long-term stability. Its commitment to quality, innovation, and customer satisfaction has helped it earn trust among medical practitioners and establish a strong foothold in the pharmaceutical industry.